BASF to spend €200m to up ibuprofen capacity in Europe and US

By Gareth Macdonald contact

- Last updated on GMT

iStock/Zerbor
iStock/Zerbor

Related tags: Pharmaceutical drug, Pharmacology

BASF has said it will build an ibuprofen plant in Ludwigshafen, Germany and increase production capacity for the API at a facility in Bishop, Texas in the US.

The German chemicals firm described the new facility – which is due to be operational in 2021 – as the “first world-scale ibuprofen plant in Europe​.”

BASF said the Texas plant expansion is designed to "fill current supply gaps for ibuprofen in the market​" adding that the "expansion will come onstream in early 2018​."

The company said it will invest approximately €200m ($227m) in both projects.

Ibuprofen is one of only a handful of active pharmaceutical ingredients (APIs) that BASF still makes. 

The firm sold most of its drug ingredient portfolio and several manufacturing facilities to Swiss firm Siegfried Holdings in 2015​. The only APIs that BASF retained, in addition to ibuprofen, were its portfolio of omega-3 based actives. 

BASF declined to disclose its current ibuprofen production capacity when contacted by in-Pharmatechnologist, but did say it "is a market leader for Ibuprofen in regards to sales and total capacity​."

The firm also told us "the investment will create in Ludwigshafen additional jobs that number in the range of the middle double digits​."

API business

BASF's remaining API business had a mixed 2016.

In July​ last year the firm reported that lower demand for drug actives had seen sales volumes dip in its nutrition & health division.

However, in its full year report​ BASF said the division had seen sales volumes increase, explaining that "demand grew, especially in the pharmaceuticals and animal nutrition businesses​."

Related news

Show more

Related products

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

TCC TB – a new filler for direct compression

TCC TB – a new filler for direct compression

Jungbunzlauer | 09-Oct-2017 | Technical / White Paper

TCC TB is a tricalcium citrate tetrahydrate designed to function as a direct compression excipient. It combines exceptional compression characteristics,...

Related suppliers